Acurx Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2022

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2022 and 2021 were as follows:


	December 31, 2022		December 31, 2021
Accrued compensation expenses	$	542,895	$	508,343
Accrued research and development		1,405,536		229,090
Accrued professional fees		83,715		43,102
Other accounts payable and accrued expenses		29,539		63,374
Total	$	2,061,685	$	843,909